Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. by Herfarth, H H et al.
Gut 1996; 39: 836-845
Interleukin 10 suppresses experimental chronic,
granulomatous inflammation induced by bacterial
cell wall polymers
H H Herfarth, S P Mohanty, H C Rath, S Tonkonogy, R B Sartor
Abstract
Background and Aims-Interleukin 10
(IL10) inhibits monocyte/macrophage and
T lymphocyte effector functions. This
study examined the effect of systemically
administered IL10 on acute and chronic
granulomatous enterocolitis, hepatitis,
and arthritis in a rat model.
Methods-Lewis rats were injected intra-
murally with streptococcal peptido-
glycan-polysaccharide (PG-APS) polymers.
Beginning 12 hours before PG-APS
injection, rats were treated daily with
subcutaneous murine recombinant IL10
or vehicle for three or 17 days.
Results-IL10 attenuated acute entero-
colitis in a dose dependent fashion
(p<0.01). Protective effects were more
profound in the chronic granulomatous
phase with decreased enterocolitis and
markedly inhibited leucocytosis, hepatic
granulomas, and chronic erosive arthritis
(p<0.001). IL10 downregulated tissue IL1,
IL6, tumour necrosis factor a, and inter-
feron y gene expression, consistent with
the in vitro effects of IL10 on PG-APS-
stimulated splenocytes. Caecal IL1 protein
concentrations and IL2 and interferon -V
secretion by in vitro stimulated mesenteric
lymph nodes were downregulated in IL10
treated animals.
Conclusions-These results indicate that
exogenous IL10 can inhibit experimental
granulomatous inflammatory responses
and suggest that IL10 treatment could be
an effective new therapeutic approach in
human disorders such as Crohn's disease,
rheumatoid arthritis, and sarcoidosis.
(Gut 1996; 39: 836-845)
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Inflammatory processes play a central part in
mediating immune host defences to infectious
pathogens and in wound healing, but an
unrestrained, overly aggressive inflammatory
response can induce inappropriate tissue
destruction. Recent observations in animal
models show that the chronicity of inflam-
mation is determined by a dysregulated balance
of pro and anti-inflammatory cytokines. 1-3
Chronic immune mediated disorders like
inflammatory bowel diseases (IBD), rheu-
matoid arthritis, and type I diabetes mellitus
seem to arise from a genetically determined
dysregulated immune response to ubiquitous
antigens.4`6 Therefore immunomodulatory
interventions that utilise endogenous immuno-
suppressive molecules provide an attractive,
relatively non-toxic approach to treating these
chronic, idiopathic disorders.
Interleukin 10 (ILIO), originally named
cytokine synthesis inhibitor factor, is a cytokine
that inhibits many immune effector functions.
IL10 is produced by a variety of cells including
T lymphocytes, B cells, and macrophages and
suppresses the in vitro production of interferon
(IFN) y and IL2 by Thi lymphocytes and IL1,
IL6, IL8, tumour necrosis factor (TNF) a,
granulocyte-macrophage colony stimulating
factor, and granulocyte colony stimulating
factor by monocytes/macrophages.7 8
Several in vivo findings in experimental
animal models suggest that ILl 0 is an
important anti-inflammatory agent. Increased
IL10 gene expression correlates with recovery
in experimental autoimmune encephalomyelitis9
and recombinant IL10 treatment attenuates
the clinical course of this disease.'0 Spon-
taneous intestinal inflammation occurs in IL10
deficient (knockout) mice" and continuous
administration of IL10 attenuates experi-
mental colitis in a lymphocyte transfer model.'2
Furthermore, IL10 therapy prevents early death
and pancreatic necrosis in models of experi-
mental endotoxaemia'3 and acute pancreatitis14
respectively, probably by down regulating
TNFoa. Finally, blockade of endogenous IL10
increases the severity of experimental arthritis
in mice."
Peptidoglycan-polysaccharide (PG-PS) poly-
mers, the basic structural component of the cell
walls of Gram positive and Gram negative
bacteria, induce acute inflammation, which in
the susceptible host proceeds into a relapsing,
granulomatous inflammatory reaction in several
organs.'1'9 The granulomatous enterocolitis
model in susceptible Lewis rats is characterised
by chronic, transmural, spontaneously relapsing
intestinal inflammation, accompanied by hepatic
granulomas, erosive arthritis, chronic anaemia,
and leucocytosis.'7 Inflammation is induced by
subserosal (intramural) injection of PG-PS
from group A Streptococcus pyogenes (PG-APS)
into the terminal ileum and caecum. Inflam-
mation in this model follows a biphasic
course. The acute phase of focal intestinal
inflammation peaks one to three days after
PG-APS injection, then gradually resolves, but
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reactivation with extensive granulomatous
intestinal and systemic inflammation. ILI is
involved in the pathogenesis of acute and
chronic phases of this model because caecal
ILI concentrations are increased and ILI
receptor antagonist (IL1 RA) treatment
attenuates inflammation.'7 T lymphocytes are
necessary for the chronic granulomatous phase
of PG-APS induced inflammation, as cyclo-
sporin A completely prevents chronic inflam-
mation and granuloma formation in the gut,
liver and joints, and athymic animals fail to
develop chronic inflammation after PG-APS
injection.2022
Because T lymphocytes and pro-inflammatory
cytokines such as ILI are involved in the
pathogenesis of intestinal, liver, and joint
inflammation in the PG-APS model, we
postulated that ILl 0 therapy should exert a
protective effect. In this study we examined the
ability of recombinant murine ILl0 to prevent
intestinal and systemic inflammation in the
PG-APS enterocolitis model and investigated
the in vivo and in vitro effects of IL10 on the
regulation of key pro-inflammatory cytokines.
Methods
Animals and reagents
Female, inbred specific pathogen free Lewis
rats (145-155 g) were obtained from Charles
River Laboratories (Raleigh, NC). Rats were
fed Agway Prolab rat chow (Agway, Syracuse,
NY) ad libitum and were weighed daily. All rat
experiments were conducted in accord with the
highest standards of humane animal care as
outlined in the National Institutes of Health's
Guidefor the Care and Use ofLaboratory Animals
and approved by the University of North
Carolina Institutional Animal Care and Use
Committee.
Recombinant murine IL10 (Batch 3-mIL
10-3 specific activity 65 X 106 U/mg; Batch
3-mIL 10-5 specific activity 45X 106 U/mg)
was obtained from Schering-Plough Research
Institute (Kenilworth, NJ).
Preparation ofPG-APS
Purified, sterile PG-APS fragments from the
cell walls of group A, type 3, strain D58
streptococci (Streptococcus pyogenes) were pre-
pared as described previously23 and provided
by Roger Brown and Dr John Schwab
(Department of Immunology and Micro-
biology, University of North Carolina, Chapel
Hill). Sonicated cell wall fragments by this
method have molecular weights ranging from
5X 106 to 5X 108.23 The final PG-APS concen-
tration was calculated based on rhamnose
content.23
Cytokine expression in vitro by splenocytes from
Lewis rats
Splenocytes (5 X 106 cells/ml) were cultured for
six hours in the presence of PG-APS (50
,ug/ml) and IL10 (0, 1, 5, 50 or 250 ng/ml).
The culture medium was RPMI 1640
supplemented with 5% heat inactivated fetal
calf serum, 2 mM glutamine, 5 X 10-6 M
2-mercaptoethanol, 100 units/ml penicillin G,
1000 ,ug/ml streptomycin sulphate, and 0.25
,ug/ml amphotericin B. Total RNA was isolated
using Trizol (Gibco, Grand Island, MY) and
stored at -80°C until further processing.
Induction of enterocolitis by PG-APS
Lewis rats, randomised into treatment
groups, were anaesthetised (20 gil/100 g by
intramuscular injection Innovar-Vet; Pitman
Moore, Washington Crossing, NJ), and intes-
tines were exposed by laparotomy using aseptic
technique. Rats were injected subserosally with
PG-APS using a total dose of 12.5 pug/g body
weight rhamnose (equivalent to 37.5 ,ig dry wt
PG-APS/g body weight) distributed among
seven injection sites in the ileal Peyer's patches,
terminal ileum, and caecum as previously
described.24 Control rats received identical
injections of 37.5 ,ug/g/body weight human
serum albumin (HSA) (Baxter Health Care
Corp, Glendale, CA).
ILIO treatment and experimental design
Recombinant murine ILIO was administered
by subcutaneous injection in different concen-
trations (100 ,ug or 250,g/kg/24 h in the acute
phase experiment or 125 pug/kg/12 h in the
chronic phase experiment) in 0.3 ml sterile
NaCl. Control PG-APS and HSA injected
animals received rat serum albumin (RSA)
(Sigma, St Louis, MO) subcutaneously in
different concentrations (250 ,ug/kg/24 h in the
acute phase experiment or 125 pug/kg/12 h in
the chronic phase experiment) dissolved in
0.3 ml sterile NaCl. In both studies treatment
was started 12 hours before PG-APS or HSA
intramural injection and given for the next
three or 17 days respectively, in the above
described scheme.
Clinical assessment ofinflammation and
harvesting of tissues
After three (acute phase) or 17 (chronic phase)
days all rats were killed by inhalation of 100%
CO2. Cardiac blood was obtained for cell
counts, which were processed using an
automated cell counter. Liver and spleen
weights were recorded and normalised for the
individual rat body weight. Gross intestinal
inflammation was scored by a single blinded
observer using a previously validated method. 17
Values of 0-4 (4 being the most severe) were
assigned to the (a) presence of caecal serosal
nodules, (b) severity of contracted mesentery,
(c) severity of adhesions, and (d) extent of
caecal bowel wall thickening. The resulting
'gross gut score' is the sum of these values, the
maximum possible being 16. Additionally the
macroscopically visible number of liver granu-
lomas was assessed by assigning a value from
0-4. Caecal, mesenteric lymph node and liver
tissues were snap frozen in isopentane and kept
at -80°C for later mRNA and protein analysis.
Samples of the liver, terminal ileum, caecum,
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and joints from each animal were fixed in
formalin, embedded in paraffin wax, and sec-
tioned for histochemical staining (haematoxylin
and eosin).
Monitoring of arthritis
Arthritis was monitored clinically (erythema,
swelling) and by measuring the diameters of
both rear ankle joints with a Fowler Ultra-Cal.
II caliper (Lux Scientific Instrument Corp,
New York, NY) as described previously.23 25
Joints were measured before PG-APS injection
and serially thereafter. To reduce bias, all
groups were coded, and the rats were selected
randomly from the cages, so that no identi-
fication was visible to the person making the
measurements. Data were expressed as the
increase of joint diameter in mm compared
with the baseline measurement before PG-APS
or HSA injection.
Histological and biochemical evaluation of
inflammation
A histological inflammatory score was evaluated
for each animal by a blinded observer as
described previously.'7 Briefly, values from 0-4
(4 being the most severe) were assigned for
both acute and chronic inflammation in the
different layers of the intestine in coded cross
sections of the terminal ileum, mid caecum,
and caecal tip. The acute and chronic scores
of each animal were totalled, a score of 24
representing the maximum possible histo-
logical inflammatory score.
Measurement of myeloperoxidase activity
Caecal myeloperoxidase (MPO) activity was
determined using a modified standard method.26
Briefly, caecal tissue was homogenised in 4 ml
20 mmol/l phosphate buffer (pH 7.4) and
centrifuged at 4000 rpm at 4°C for 20 minutes.
The pellet was homogenised and sonicated
with 2 ml 50 mmoIl acetic acid (pH 6) con-
taining 05% (wt/vol) hexadecyltrimethyl-
ammonium hydroxide. MPO activity of the
supernatant was determined by measuring the
H202 dependent oxidation of 3,3',5,5'-tetra-
methylbenzidine and expressed as units per
gram of tissue.
TABLE I Oligonucleotide primers usedfor amplification ofdifferent cytokines by RT-PCR
5 --------Sense Primer--------3' Sample Annealing
mRNA 5'--------Antisense Primer-------3' cDNA temperature
IFNy 5'-AAG ACA ACC AGG CCA TCA GCA-3' 547 bp 600C
5'-AGC CAC AGT GTG AGT TCA GTC-3'
5'-ATG GAA GGA AAG AGC CTC CTC-3' 225 bp 600C
5'-CT GGC GAT GCT CAT GAA TGC-3'
TNFa 5'-CAC CAT GAG CAC GGA AAG CA-3' 692 bp 580C
5'-GCA ATG ACT CCA AAG TAG ACC-3'
IL6 5'-CTT CCA GCC AGT TGC CTT CT-3 504 bp 60`C
5'-GAG AGC ATT GGA AGT TGG GG-3'
ILla 5'-TCC TGT GAC TCT CAA AGT CTC-3' 362 bp 580C
5'-ATG CGA GTG ACT TAG GAC GA-3
IL13 5'-GCT ACC TAT GTC TTG CCC GT-3' 543 bp 580C
5-GAC CAT TGC TGT TTC CTA GG-3'
IL1 RA 5'-CTG GGA TAC TAA CCA GAA GAC C-3' 367 bp 580C
5'-TGG TGT GTT GGT GAG GCT CAC-3'
1B actin 5'-ACC ACA GCT GAG AGG GAA ATC G-3' 281 bp 60`C
5-AGA GGT CTT TAC GGA TGT CAA CG-3'
RNA preparation
Total tissue RNA was prepared using a
standard method with guanidine thiocyanate-
cesium chloride as previously described.'7 Total
RNA was quantified by ultraviolet spectro-
photometry (A260/A280). The integrity and
quality of each RNA sample was checked by
electrophoresis on a 1% agarose gel containing
ethidium bromide.
Polymerase chain reaction (PCR)
For each sample 1 ,ug of total RNA was reverse
transcribed in a total volume of 25 gl con-
taining lXfirst strand buffer (Gibco, Grand
Island, NY) 125 U of Moloney murine
leukaemia virus RT (Gibco, Grand Island, NY),
15 U RNAse inhibitor (Promega, Madison,
WI), 0.5 mM each of four dNTPs (Pharmacia,
Piscataway, NJ), and 5 pmol of random
Hexamers (Pharmacia, Piscataway, NJ). The
reaction was carried out at 39°C for one hour,
followed by 93°C for seven minutes, 24°C for
one minute, and finally cooled down to 4°C for
30 minutes. The reaction mixture was stored
at -20°C until further use.
The amplification was carried out in a 9600
Perkin-Elmer cycler (Applied Biosystem, Foster
City, CA). One to 2 ,ul of cDNA sample was
amplified in 50 ,lI of a reaction mixture
containing 1 XTaq buffer II (Perkin Elmer,
Norwalk, Co), 1.5 mM MgCl2, 2 pLM each of
5' and 3' primers and 1 U ofTAQ polymerase
(Perkin Elmer, Norwalk, CO). Samples were
heated for four minutes at 94°C and the
following cycles were conducted at 94°C for
45 seconds, 60°C for 45 seconds, 72°C for 1.30
minutes. At the end the reaction mix was held
at 72°C for five minutes. Negative controls
without cDNA were amplified with each PCR
experiment. To confirm that equal amounts of
RNA were added in each PCR within an
experiment and to verify a uniform amplifi-
cation process P actin mRNA was reverse tran-
scribed and amplified in each assay. Aliquots of
the samples were analysed by electrophoresis
on a 2% agarose gel containing ethidium
bromide. The DNA products were visualised
by ultraviolet fluorescence and photographs
of the gels were taken with a negative film
(Polaroid 665, Polaroid Corp, Cambridge,
MA). The negative was scanned with a Silver-
scanner II PS v2.Aa using Adobe Photoshop
2.5.1 software.
Primers specific for rat cytokines were con-
structed according to published sequences27~33
and are listed in Table I. The authenticity of
the PCR product was confirmed by comparing
actual and predicted size using a 100 bp DNA
ladder (Gibco) and by observation of frag-
ments of predicted sizes after digestion with
the listed restriction enzymes: EcoR I (IFNy),
TAQ I (TNFac, ILI RA), BgI II (IL6), Acc I
(IL1 at), BamH I (IL>).
Cell cultures of mesenteric lymph nodes (MLN)
Mesenteric lymph nodes from rats treated with
IL10 or the vehicle were removed, gently
minced, and filtered through a fine mesh.
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The cells were washed and resuspended
(5X 106 in 1 ml) in RPMI and additives as
described above. The cells were cultured at
37°C in 5% CO2 and 95% 02 in a 24 well
tissue culture plate for 10 or 36 hours in the
presence or absence of concanavalin A
(1 ,ug/ml), after which the supematants were
collected for the assays. Experiments were
performed with cells from at least three
individual animals.
Cytokine assays
ILla: Caecal tissues were homogenised in ice
cold 20 mmol/l phosphate buffer (pH 7.4) and
the supernatant kept at -80°C until assay. The
homogenates were measured in 1:1 dilutions
using a radioimmunoassay kit for rat ILlcx
(Cytokine Science, Boston, MA).
IFNy activity was measured by a rat IFNy
ELISA (Biosource Int; Camarillo, CA).
IL2 was measured in a bioassay using the
murine cell line designated NK. Briefly,
titrated amounts of culture supematants were
added to NK cells (5 X 103 cells/well in 100 ,l
culture volume) and incubated for 48 hours.
The cultures were pulsed with 3H-thymidine
for the last four hours. Cells were harvested
and incorporation of 3H-thymidine was de-
termined by scintillation counting. Units per
ml of IL2 are defined as the reciprocal of the
dilution of supematant that stimulates 50%
of the maximal counts per minute of
3H-thymidine incorporation, multiplied by 10
as the bioassay volume is 0 1 ml.
Statistical analysis
Data were analysed using a statistical software
(Statview II; Abacus Concept, Berkely, CA).
Differences between the groups were com-
pared using one way analysis of variance or
using x2 analysis. Differences were considered
significant if p values were <0 05.
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Figure 1: Semiquantitative RT-PCR analysis of the regulation ofcytokine gene exp
in isolated splenocytes by ILI 0. Splenocytes were isolatedfrom Lewis rats and stimu
with 50 ,g/ml PG-APS with or without different concentrations ofIL10 (50 or 250
Total RNA was isolated after six hours, reverse transcribed, and the cDNA was dill
10-fold steps (1:1, 1:10, 1:lOOfor ILIla, IFNy, TNFa or 1:10, 1:100, 1:1000 fox
Using specific oligonucleotide primers, amplification was performedfor 35 (Actin, I
40 cycles (IFNy, TNFa) and aliquots of the products were visualised on a 2% aga
with ethidium bromide. (BPL= 100 base pairDNA ladder). Representative gels of
independent experiments are shown.
Results
In vitro inhibition of cytokines by ILIO
To demonstrate the potential anti-inflammatory
role of recombinant murine IL10 on rat cells
stimulated with PG-APS, we isolated spleno-
cytes from Lewis rats and added 50 ,ug/ml
PG-APS and different concentrations of ILIO
for six hours. PG-APS markedly upregulated
IFNy, ILlox, and TNFo gene expression in
splenocytes in vitro (Fig 1). Fifty and 250 ng/ml
recombinant murine ILl 0 inhibited gene
expression ofIFNy, ILlot, and TNFa in a dose
dependent fashion (Fig 1), whereas lower
doses (1 or 5 ng/ml) were ineffective (results
not shown).
Effects ofILIO treatment on the acute
inflammatory phase
Two different doses of recombinant murine
IL10, 100 or 250 jig/kg, were administered
daily by subcutaneous injection, starting 12
hours before surgery. Three days after surgery,
the rats were killed and the inflammatory
changes of the intestine were scored in a
blinded fashion. An amelioration of the gross
gut score (GGS) with a significant benefit by
the higher IL10 dose (250 ,ug/kg) was observed
(Fig 2A). In the analysis of the different
components of the GGS, the most significant
improvement was in decreased caecal thicken-
ing (mean (SEM)) (1.9 (0.1) PG-APS/IL10
250 ,ug/kg versus 2.3 (0.1) PG-APS/RSA;
p<0. 01). Adhesions and mesenteric contractions
improved with IL10 treatment, but were
not significantly better than control values.
Surprisingly, caecal MPO values were signifi-
cantly increased with the higher ILIO dose
compared with the control group (p<0 05)
(PG-APS/RSA: 4.5 (04) units/g; PG-APS/
IL10 100 jig/kg: 5.7 (0.6) units/g; PGPS/IL10
250 jig/kg: 6.0 (0.4) units/g; HSA/RSA: 3.1
(0.5) units/g) and histological examination of
selected animals showed no difference between
the IL10 treated and untreated PG-APS
injected groups (results not shown). ILl0
treatment ameliorated the acute arthritis, but
the differences between the groups were not
significant due to the low incidence of acute
arthritis after intestinal intramural PG-APS
injection.17 Furthermore, there were no differ-
ences in body weight, liver weight, packed cell
volume or white blood cell count between the
groups.
Effects ofIL1O on the chronic inflammatory
** phase
Using the higher ILIO dose (250 ,ig/kg/24 h),
which exhibited greater protective effects on
H20 gross intestinal inflammation in the acute phase,
we investigated whether continuous IL10
ression administration for 17 days had a protective
elated effect in the T lymphocyte dependent, chronic
uted in phase of this model. Because a recently
rActin). published study showed better effects of IL10
Lla) or treatment when given at shorter time inter-
roseegel vals,34 we administered divided doses of IL10three
(125 pig/kg/12 h).
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Figure 2: (A) In vivo administration ofIL10 (100 ,ug/kg
or 250 ,ug/kg every 24 hours subcutaneously) shows a dose
dependent effect on acute intestinal inflammation in the
PG-APS model. ILI 0 or RSA treatment was started 12
hours before subserosal PG-APS orHSA injection and
then was continuedfor three days. The gross gut score was
made by a single blinded observer at necropsy on day 3.
HSA=human serum albumin; RSA=rat serum albumin;
PG-APS=peptidoglycan-polysaccharide polymers
isolatedfrom groupA Streptococcus pyogenes. *p<0 01
PG-APSIIL10 v PG-APS/RSA. (B) In vivo subcutaneous
administration ofIL10 (125 ,ug/kg every 12 hours)
significantly reduces chronic macroscopic gut inflammation
17 days after PG-APS orHSA injection. *p<0.003
PG-APS/ILI 0 v PG-APSIRSA.
Chronic intestinal inflammation
IL10 significantly reduced grossly detectable
intestinal inflammation by more than 40% in
the chronic granulomatous phase of PG-APS
induced enterocolitis (p<0-003) (Fig 2B). In
contrast with the acute phase significant
improvement was observed in all parameters of
the gross gut score, including thickening of the
bowel wall, caecal nodules, intestinal adhesions,
and mesenteric contractions. By histological
assessment significant differences were seen
between the treated and untreated PG-APS
injected groups in both the acute (neutrophilic
cell infiltration and abscess formation) and
chronic components (mononuclear cell infil-
tration and granuloma formation) (Table II).
IL10 treatment resulted in a 30% decrease in
the total (summed) histological inflammatory
score (p<0-03). The improvement of the acute
score with IL10 treatment was more pro-
nounced in the terminal ileum than in the
caecum, where only a trend could be observed.
The small suppression of neutrophil infil-
tration in the caecum by IL10 was also
reflected by caecal MPO values, which showed
only a slight, non-significant improvement
in the treatment group (PG-APS/RSA: 12-1
(1.0) units/g; PG-APS/IL10 250 ,ug/kg: 11.8
(1.7) units/g; HSAIRSA: 2.7 (0.5 units/g).
Chronic extraintestinal inflammation
Extraintestinal inflammation was inhibited by
IL10 to a greater extent than enterocolitis.
Eighty per cent of the PG-APS/RSA group had
macroscopically visible liver granulomas, com-
pared with only two of 10 animals in the
PG-APS/IL10 group (p<0-001). Histological
analysis showed that one additional IL10
treated rat had scattered hepatic granulomas,
which were not visible by macroscopic
evaluation (Table III). However, these three
IL10 treated animals showed considerably less
hepatic inflammation than the PG-APS/RSA
animals in regard to histological distribution
and destruction of liver parenchyma. Although
parenchymal granulomas were only rarely seen
in the liver ofIL10 treated rats, a mononuclear
cell infiltrate was observed around bile ducts
(Fig 3). The increase in liver weight of
PG-APS injected/ILl 0 treated rats compared
with non-PG-APS injected controls was
decreased by 45% (p<0-03) (Table III), con-
firming a beneficial effect of IL10 on hepatic
inflammation. Similar beneficial effects of
IL10 treatment were seen on haematological
parameters, which are reliable indices of
intestinal and systemic inflammation in this
model.'7 Peripheral leucocytosis and anaemia
were significantly attenuated by ILIO admin-
istration (p<0-004) (Table III). No effect was
noted on body weights, which were not
different between PG-APS and HSA injected
groups.
TABLE II ILI0 treatment suppressed inflammation in the gut 17 days after PG-APS injection as assessed by histological
inflammatory scores of the intestine
Terminal ileum Caecum Histological inflammatory score
Groups
Gut injection/treatment acute chronic* acute chronic acutet chronic Histological scorest
PG-APA/RSA (n=10) 3-8 (0-1) 3-7 (0-8) 7-0 (0-2) 7-4 (0-2) 10-9 (0-2) 11-1 (0-2) 22-0 (0-5)
PG-APS/IL10 (n=10) 2-4 (0-6) 2-6 (0-4) 5-1 (1.1) 5-2 (0-9) 7-6 (1-5) 7-8 (1-2) 15-4 (2-8)
HSA/RSA (n=5) 0 0 0 0 0 0 0
p Value§ <0-03 <0-02 <0-04 <0-05 <0-02 <0-03
*Mean (SEM). tSummation of distal ileal and caecal blinded histological scores (0-4), as described in the methods section.
*Summation of acute and chronic score. §p Values: PG-APS/IL10 v PG-APS/RSA group.
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Groups WBC PCV Liver weight
Gut injection/treatment X 1O SI units/l % mg/g body weight macroscopic histological
PG-APS/RSA (n=10) 29-7 (2.6)* 37-8 (1.0) 70-5 (4.6) 80% 80%
PG-APS/IL1O (n=10) 17-3 (1-7) 42-7 (1.1) 56-5 (3.6) 20% 30%
HSA/RSA (n=5) 7-7 (0.4) 48-4 (0.7) 39-7 (1-2) 0% 0%
p Value§: <0-001 <0 004 <0 03 <0-01 <0-02§
*Mean (SEM); tincidence of hepatic granulomas; tp values PG-APS/IL10 v PG-APS/RSA; §p values PG-APS/IL10 v
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Days after PG-APS injection
Figure 4: Effect ofmurine recombinant ILI 0 treatment on
PG-APS induced arthritis. IL10 (125 pug/kg every 12
hours) was given subcutaneously starting 12 hours before
PG-APS injection (12.5 ,ug/g subserosally in the intestine)
and continuing throughout the duration of the experiment
(n=10). Controls included rats injected intramurally
with PG-APS (n=10) orHSA (n=5) and treated
with RSA (125 ,g/kg every 12 hours subcutaneously).
J7oint measurements were carried out at indicated days
after PG-APS injection. J7oint diameter changes in
PG-APS/RSA treated rats were significantly greater
(*p<0.01) than PG-APS/IL10 treated rats at each
interval after day 10.
Figure 3: Histological demonstration of the liver architecture
17 days after subserosal PG-APS injection and RSA
treatment (A) or continuous murine recombinant IL10
treatment (B). Only infiltration ofmononuclear cells in
the area of the portal tract are visible in liver sections of
PG-APS/IL10 treated rats, whereas the livers of
PG-APSIRSA treated rats show destruction of the
architecture with granulomas (haematoxylin and eosin
stain, original magnification X 20).
Murine recombinant IL10 treatment sup-
pressed the development of chronic arthritis in
a highly significant fashion (Fig 4). On day 17
after PG-APS injection joints of IL10 treated
rats were not significantly increased over
HSA/RSA negative controls; the increase in the
mean (SEM) joint diameter from preinjection
values seen in the PG-APS/RSA group was
reduced by nearly 80% (1.85 (0.37) mm in
the PG-APS/RSA versus 0.38 (0.19) mm in
the PG-APS/IL10 treatment group, p<0-001)
(Fig 4). Only two of 10 animals showed clinical
signs of arthritis after IL10 treatment with very
attenuated arthritis in one of the two rats,
whereas eight of 10 animals in the PG-APS/
RSA group clinically showed profound arthritis
with marked swelling and erythema. The histo-
pathology of the joints confirmed the clinical
pattern. Figure 5 shows that infiltration of
PMNs and mononuclear cells, pannus for-
mation, cartilage erosion, bone degradation as
well as exudation of cells into the joint space
were clearly inhibited by IL10 treatment.
A'.. -
Figure 5: Representative joint tissuesfrom rats treated with
RSA (A) or recombinant murine IL10 (B) for 17 days
after intestinal subserosal PG-APS injection. I1140
treatment prevented clinical and histological (B) onset of
arthritis, whereas the histological section of only RSA
treated rats show pannus formation with infiltration of
neutrophils, and mononuclear cells, as well as cartilage
destruction and bone erosion (A) (haematoxylin and eosin
stain, original magnification X 20).
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Effects ofILJO treatment on cytokine regulation
IL10 reduced or inhibited the expression of
ILla and P, TNFac, IL6, and IFNy genes in
the liver, mesenteric lymph nodes, and caecal
tissues as measured by RT-PCR. The most
pronounced effects were seen in the liver con-
sistent with the marked differences in hepatic
granuloma formation (Fig 6). Expression of
IL1 RA and ILIO mRNA (results not shown)
did not differ between the IL10 treated and
not treated groups; these cytokines were
also constitutively expressed in non-inflamed
HSA/RSA controls.
Earlier studies showed significantly increased
ILlot protein concentrations in caecal tissues in
the chronic phase after PG-APS subserosal
injection.'7 IL10 treatment decreased ILla
protein levels by 40% (Fig 7). Furthermore, we
assessed the production of IFNy and IL2 by
concanavalin A stimulated MLN cells, isolated
17 days after PG-APS injection. Whereas MLN
cells showed no measurable spontaneous pro-
duction ofIFNy or IL2, concanavalin A stimu-
lation upregulated the production of IFNy
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Figure 7: Caecal ILIa protein levels measured by
radioimmunoassay in caecal tissues 17 days after injection
ofPG-APS or HSA. ILIa protein concentrations are
expressed as mean (SEM). ILIO treatment inhibited ILIa,
whereas PG-APS alone significantly increased caecal ILla
protein levels compared with the HSA control group
(*=p<0003 PG-APS/RSA v HSA/RSA).
treated rats compared with HSA/RSA controls. a greater effect on chronic, granulomatous
However, concanavalin A stimulated MLN enterocolitis than on the acute phase of inflam-
cells isolated from ILIO treated rats showed a mation. ILIO treatment significantly improved
45% reduction of IFNy and IL2 production macroscopic, histological, and immunological
from PG-APS/RSA treated animals. parameters of chronic intestinal inflammation
17 days after PG-APS injection. The improve-
ment in neutrophilic infiltration was less pro-
Discussion nounced, as reflected by only minor changes of
This study shows that murine recombinant caecal tissue myeloperoxidase levels, although
ILl0 treatment successfully attenuated acute the acute histological score in the ileum (but
and chronic granulomatous inflammation not the caecum) was significantly decreased
induced by bacterial cell wall polymers and with ILl0 treatment. These results suggest
downregulated cytokine expression in vivo and that ILl 0 treatment affects mononuclear cell
in vitro. Continuous IL10 administration had (lymphocytes and macrophages) infiltration to
a greater extent than neutrophils, in agreement
- I I with two previously published studies.'434
In murine acute pancreatitis IL10 did not
influence cellular infiltration despite inhibiting
tissue necrosis.'4 Furthermore, IL10 treatment
did not improve the morphology or degree of
cellular infiltrate in footpads injected with ThI
lymphocytes in a murine model of delayed type
I_- - hypersensitivity,34 albeit IL10 inhibited foot-
pad swelling by decreasing vascular per-
meability. Although we did not quantitate the
degree of oedema or vascular leakage in this
study, the significant improvement in acute
macroscopic inflammation was mainly due to
decreased bowel wall thickening, correspond-
ing with observations in the delayed type
hypersensitivity model.
The macroscopic and histological improve-
- I 1 1 ment of chronic inflammation by ILlO treat-
ment was accompanied by a down regulation
of gene expression of monokines as well as
- IFNy in tissues, consistent with the ability of
IL10 to inhibit expression of these cytokines by
PG-APS stimulated splenocytes in vitro. These
HS4A/ PG-APS/ PG-APS/ IH0 results agree with the ability of IL10 to inhibit
IRSA I IL10 RSA I 2 macrophage and lymphocyte activation7 and to
ession of different cytokines in the liver ofILI 0 treated PG-APS increase survival in a model of endotoxaemia
pared with PG-APS/RSA and HSA/RSA animals. Shown are three by downregulating TNFot. "
zls ofeach group. On day 17 RNA was isolatedfrom liver tissues and The effects ofIL10 treatment on in vivo gene
d using RT-PCRfor 23-40 cycles with rat cytokine specific primers.
cts were visualised on a 2% agarose gel. To confirm a uniform expression of the monokines ILl, IL6, and
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parallel with a marked inhibition of hepatic
granulomas. Kupffer cells and newly recruited
monocytes are important in the genesis of
hepatic granulomas after intraperitoneal injec-
tion of PG-APS.35 36 Kupffer cells rapidly clear
these bacterial polymers from the circulation
and large amounts of PG-APS remain in the
phagolysosomes of these cells after 14-21
days.36 Our studies suggest that continuous
IL10 administration to PG-APS treated rats
downregulates monokine production by acti-
vated Kupffer cells and mononuclear phago-
cytes, thereby inhibiting formation of hepatic
granulomas. This hypothesis is supported by
in vitro studies showing that isolated Kupffer
cells secrete ILI and TNFcL after stimulation
with PG-APS36 37 and that LPS or PG-APS
stimulated TNFc. secretion by Kupffer cells
can be inhibited by ILl0 (38 and H Herfarth,
S Lichtman unpublished results).
IL10 nearly completely prevented chronic
arthritis in this model, probably by down
regulation of IL1, IL6 or TNFox, as shown in
the liver. A role for these macrophage products
in the pathogenesis of experimental arthritis
is demonstrated by reactivation of PG-APS
induced arthritis by systemic injections of IL1
or TNFPc and by induction of acute, transient
arthritis by intraarticular injection of ILlot
or (.25 39 40 Furthermore, treatment with
recombinant ILl RA or anti-TNFa antibody
inhibits PG-APS induced arthritis,39 as does
systemic treatment with TGF.4' In vitro
TGF(3 decreases LPS induced macrophage
production of TNFax and IL1 to a similar
extent as ILl0, but inhibits cytokine
translation in contrast with the activity of IL10
on transcriptional downregulation.42 IL1, IL6,
and TNFot are also implicated in the patho-
physiology ofhuman rheumatoid arthritis5 and
blocking endogenously produced IL10 in
synovial cultures markedly increased these
cytokines, suggesting an important immuno-
regulatory role of IL10 in the joint.43 It is likely
that IL10 has a similar key role in maintaining
mucosal homeostasis, as targeted deletion of
this cytokine leads to spontaneous intestinal
inflammation.`
IL10 treatment more successfully inhibited
extraintestinal inflammation in liver and joints
than in the intestine, similar to the therapeutic
effects of IL1 RA in this model.'7 The amount
of PG-APS in various organs may be a critical
component because concentrations of this
polymer are highest at intestinal injection
sites.24 Another variable is tissue concen-
trations of the administered IL10 within the
various inflamed organs, which could not be
measured in this study. Given the ability of
PG-APS to activate multiple inflammatory
pathways'9 and the redundancy of many
immunological processes,4 44 45 treatment with
IL10 alone might not be sufficient to com-
pletely suppress aggressive enterocolitis. An
additional anti-inflammatory agent may be
necessary to provide synergistic benefit. This
concept is elegantly demonstrated by Powrie
et al, who showed in a delayed type hyper-
sensitivity model that the combination of
IL4 and IL10 is more effective than
monotherapy.46 In preliminary investigations,
we have demonstrated additive activities of
IL10 and corticosteroids in the PG-APS
model.47
ILIO suppresses Thl cytokine production48
as well as Thl lymphocyte proliferation
in vitro,49 if macrophages are used as antigen
presenting cells. IL4, however, seems to be
more important than IL10 in crossregulating a
Thl response towards a Th2 response.50 The
crucial role of T lymphocytes in chronic
intestinal and systemic inflammation in the
PG-APS model is well documented.20-22 51 In
our model in vivo IL10 treatment down-
regulated IFN-y and IL2 protein secretion of
mesenteric lymph nodes after Con A stimu-
lation and inhibited tissue IFNy gene ex-
pression. Furthermore in vitro ILIO decreased
IFN-y upregulation in PG-APS activated spleno-
cytes. Negative regulation of IFNy by ILIO is
the suggested mechanism of disease prevention
in the experimental allergic encephalomyelitis
model'0 and in the non-obese diabetic mouse
model.52
As shown here, IL10 downregulated expres-
sion of several pro-inflammatory cytokines
in vivo. However, we cannot determine if these
protective effects are direct or indirect through
induction of other inhibitory cytokines, like
ILI RA, or by inhibition of pro-inflammatory
mediators like IL1 2. IL1 RA, which attenuates
PG-APS induced enterocolitis and systemic
inflammation,'7 25 is upregulated in the pres-
ence of IL10 in LPS activated neutrophils,53
whereas IL10 had no effect on IL1 RA pro-
duction by mononuclear cells isolated from
patients with rheumatoid arthritis54 or in vitro
endotoxin stimulated whole blood from healthy
volunteers after intravenous ILIO admin-
istration.55 In our study, tissue ILI RA mRNA
expression was not affected by IL10 treatment,
but by downregulating IL1 production, IL10
increased the ratio between IL1 RA and IL1
towards a protective environment. A similar
shift towards an immunosuppressive ratio of
IL1 RA/IL1 was recently demonstrated in
isolated mononuclear cells from patients with
Crohn's disease exposed to I10.`56 IL10 also
downregulates the pro-inflammatory cytokine
IL12,57 which is involved in the pathogenesis
of intestinal inflammation, as recently shown
by the successful treatment of experimental
colitis by IL12 antibodies.58 IL12 is secreted by
activated macrophages and B cells and strongly
increases IFNy production by T lymphocytes,
thus shifting the immunological response
towards a Thl repertoire, as recently shown in
a parasitic experimental model.59
The PG-APS model, which displays geneti-
cally determined host susceptibility, ileocaecal
inflammation, extraintestinal manifestations of
anaemia, leucocytosis, hepatobiliary inflam-
mation, arthritis, and exhibits spontaneous
relapses of inflammation, resembles many
features of Crohn's disease. Furthermore,
PG-APS is an environmentally relevant agent,
which is present in high concentrations in
the lumen of the distal ileum and colon.
Ubiquitous anaerobic bacteria and their cell
wall components seem to be involved in IBD
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and reactive arthritis.'9 60 Our results demon-
strate that IL10 down regulates experimental
chronic granulomatous inflammation induced
by bacterial cell wall components in genetically
susceptible hosts. In this model IL10 appears
to act by suppressing the expression of mono-
kines and IFNy. Immunomodulating IL10
treatment could be a new effective therapeutic
approach for chronic inflammatory diseases
in humans, particularly Crohn's disease and
rheumatoid arthritis, which are charac-
terised by increased tissue concentrations of
products of activated macrophages and Thl
lymphocytes.5 44 61
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